Product Information
BUPROPION HCL XL 300 MG TABLET is a generic product labeled by BluePoint Laboratories, priced at $0.1073 per EA under NDC 68001052003. Its NADAC has been published 200 times since Jun 8, 2022.
FDA first approved this application on Oct 31, 2018. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
BluePoint LaboratoriesNDC
68001052003
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
3/18/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210497FDA Approved
10/31/2018
TE Code
AB3
On Market Since
12/13/2021
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL XL 300 MG TABLET has been published 200 times since Jun 8, 2022, and over the history we have for it it has declined 39.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1073 per EA |
|---|---|
| All-time high | $0.1988 (Feb 14, 2024) |
| All-time low | $0.1033 (Feb 18, 2026) |
| 52-week high | $0.1492 |
| 52-week low | $0.1033 |
| Median price | $0.1522 |
| Average price | $0.1541 |
| Largest weekly change | -27.4% (Feb 21, 2024) |
| Weeks tracked | 200 |
| Tracking since | Jun 8, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
+3.9%
1Y
-28.0%
3Y
-39.7%
5Y
N/A
All
-39.6%
Last surveyed Apr 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BUPROPION HCL XL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL XL 300 MG TABLET, manufactured by BluePoint Laboratories, is $0.1073 per EA (NDC 68001052003), effective Apr 1, 2026.
How has the price of BUPROPION HCL XL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL XL 300 MG TABLET has declined 39.6%. It has been tracked across 200 weekly CMS publications since Jun 8, 2022.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL XL 300 MG TABLET?
Since Jun 8, 2022, the NADAC for BUPROPION HCL XL 300 MG TABLET has ranged from a low of $0.1033 (Feb 18, 2026) to a high of $0.1988 (Feb 14, 2024), with a median of $0.1522 per EA.
Are there cheaper alternatives to BUPROPION HCL XL 300 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUPROPION HCL XL 300 MG TABLET, is $0.1014 per EA — about 6% below BUPROPION HCL XL 300 MG TABLET.
Who manufactures BUPROPION HCL XL 300 MG TABLET?
BUPROPION HCL XL 300 MG TABLET (NDC 68001052003) is labeled by BluePoint Laboratories, and CMS classifies it as a generic product.